title: Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study.
abstract: Assessment of central blood pressure (BP) has grown substantially over recent years because evidence has shown that central BP is more relevant to cardiovascular outcomes than peripheral BP. Thus, different classes of antihypertensive drugs have different effects on central BP despite similar reductions in brachial BP. The aim of this study was to investigate the effect of nebivolol, a β-blocker with vasodilator properties, on the biochemical and hemodynamic parameters of hypertensive patients.
  
  
  
  Experimental single cohort study conducted in the outpatient clinic of a university hospital.
  
  
  
  Twenty-six patients were recruited. All of them underwent biochemical and hemodynamic evaluation (BP, heart rate (HR), central BP and augmentation index) before and after 3 months of using nebivolol.
  
  
  
  88.5% of the patients were male; their mean age was 49.7 ± 9.3 years and most of them were overweight (29.6 ± 3.1 kg/m2) with large abdominal waist (102.1 ± 7.2 cm). There were significant decreases in peripheral systolic BP (P = 0.0020), diastolic BP (P = 0.0049), HR (P < 0.0001) and central BP (129.9 ± 12.3 versus 122.3 ± 10.3 mmHg; P = 0.0083) after treatment, in comparison with the baseline values. There was no statistical difference in the augmentation index or in the biochemical parameters, from before to after the treatment.
  
  
  
  Nebivolol use seems to be associated with significant reduction of central BP in stage I hypertensive patients, in addition to reductions in brachial systolic and diastolic BP.
authors: Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: Renan Oliveira
authors: RO
authors: Vaz-de-Melo
authors: Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: Luiz Tadeu
authors: LT
authors: Giollo-Júnior
authors: Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: Débora Dada
authors: DD
authors: Martinelli
authors: Department of Internal Medicine, Cardiovascular Pharmacology Laboratory, School of Medical Sciences, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
authors: Heitor
authors: H
authors: Moreno-Júnior
authors: Universidade Estadual de Ciências Médicas de Alagoas, Maceió, Brazil.
authors: Marco Antônio
authors: MA
authors: Mota-Gomes
authors: Department of Internal Medicine, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: José Paulo
authors: JP
authors: Cipullo
authors: Department of Internal Medicine, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: Juan Carlos
authors: JC
authors: Yugar-Toledo
authors: Department of Internal Medicine, Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil.
authors: José Fernando
authors: JF
authors: Vilela-Martin
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001916:Brachial Artery / Q000187:drug effects; D015331:Cohort Studies; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D010045:Outpatients; D063177:Pulse Wave Analysis
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol